An 8-Day Losing Streak Has Aehr Test Systems Stock Down 38%
A sharp, multi-day slide in the semiconductor stock puts its difficult fundamentals in the spotlight.
Aehr Test Systems (AEHR) stock has now moved lower for 8 consecutive trading days, a cumulative loss of 38%. That slide has erased about $1.8 billion from the company’s market value, which now stands at about $2.9 billion.
AEHR Versus The S&P 500, Streak And Beyond
Here is how AEHR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | AEHR | S&P 500 |
|---|---|---|
| 1D | -0.7% | 0.7% |
| 8D (Current Streak) | -37.9% | -0.2% |
| 1M (21D) | 38.3% | 5.7% |
| 3M (63D) | -9.5% | 2.2% |
| YTD 2026 | 348.0% | 12.9% |
| 2025 | 21.4% | 16.4% |
| 2024 | -37.3% | 23.3% |
| 2023 | 32.0% | 24.2% |
How does the business stack up against the market?
The company’s recent performance shows signs of strain. Revenue over the last twelve months declined 15.2%, compared to an S&P 500 median revenue growth of 8.3%. The company’s 3-year average annual revenue growth is -8.1%.
Profitability is also a challenge. The operating margin over the last twelve months is -28.3%, versus an S&P 500 median of 18.5%, and Aehr Test Systems has negative trailing earnings. This 8-day decline is the stock’s own story; over the same period, the S&P 500 returned -0.2%.
How should I think about a streak like this?
A long streak is primarily a signal of sustained market attention and momentum. It is not an instruction to buy or sell, but it does create a clear moment to re-evaluate the relationship between the company’s price and its underlying business.
The disciplined response is to weigh the facts. The data shows a company with contracting revenue and negative margins. At the same time, even after this decline, the stock is up +38.3% over the trailing one month and +249.4% over the trailing twelve months. That is the core tension for an investor to resolve.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
Prefer the theme to this single name? Our ETF Scorecard shows how the technology funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.